Navigation Links
James T. Glover Appointed to Board of Directors of Varian, Inc.
Date:5/7/2008

PALO ALTO, Calif., May 7 /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS: VARI) announced that its Board of Directors today appointed James T. Glover as a new director. Glover is the seventh member of Varian, Inc.'s board of directors, and was appointed for a term expiring at the annual meeting of the Company's stockholders in 2009.

Glover is Senior Vice President, Operations and Chief Financial Officer of Anadys Pharmaceuticals, Inc. (a biopharmaceutical company), a position he has held since 2006. Before that, from 2003 to 2006, he was Senior Vice President and Chief Financial Officer of Beckman Coulter, Inc. (a biomedical testing instruments company), where he held a variety of other finance-related positions from 1989 to 2003.

"We are very pleased to have Jim Glover as a member of the Varian, Inc. board," said Allen J. Lauer, Chairman of the Board, Varian, Inc. "His exceptional background in finance and accounting, combined with his extensive laboratory instruments and life science industry experience, will serve us well in both protecting and promoting stockholder value."

Glover earned his Bachelor of Science degree in accounting from California State Polytechnic University, Pomona, and an MBA from Pepperdine University. He is a certified public accountant and former audit manager with KPMG International.

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 4,000 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, "VARI." Further information is available on the company's Web site: http://www.varianinc.com.

For More Information, Contact:

Investor Relations

Varian, Inc.

650.424.5471

ir@varianinc.com


'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
2. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
3. Immunotec Inc. announces appointment of President & CEO James A. Northrop
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. James Webb Space Telescope marks successful completion
6. IRIDEX Announces James Mackaness Will Be Chief Financial Officer
7. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
8. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
9. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
10. Warner Chilcott Reports the Death of Its Director James Andress
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):